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Telomerase activity is upregulated in most types of 
malignant tumor. Highly selective smaIl molecule 
inhibitors will be needed to understand the biological 
basis for this observation and to determine if 
telomerase is a viable target for chemotherapy. 
Address: Howard Hughes Medical Institute, University of Texas 
Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, 
TX 75235, USA. 
Correspondence: David R Corey 
Chemistry & Biology November 1996, 3:X3-867 
0 Current Biology Ltd ISSN 1074-5521 
Questions arise whenever an enzyme activity is more 
prevalent in cancerous cells than normal cells. Why is there 
a difference? Is the activity necessary for tumor growth? 
Can ir be used as a diagnostic or prognostic marker? Can 
small molecules selectively inhibit the enzyme in cancerous 
cells? Recently, a new difference between normal somatic 
cells and cancerous cells has been noted - the presence or 
absence of telomerase activity [14]. Telomerase is an 
unusual target for chemotherapy, and deciphering’ its true 
potential will challenge chemists and biologists. The link 
between telomerase and cancer has been reviewed exten- 
sively [S-S]. Our goal here is to describe briefly the 
evidence for and against the celomerase-cancer connection 
and then to focus on the design of relomerase inhibitors. 
Telomerase function and biochemistry 
Telomeres are specialized sequences at the ends of chro- 
mosomes which are believed to protect adjacent regions of 
DNA [9]. I-fuman telomeres are composed of the repeated 
sequence GCGTTA and vary in length from 10-15 kb in 
germ line cells to S-12 kb in peripheral blood leukocytes 
[l&11]. Maintenance of telomere length poses a dilemma 
for the cellular replication machinery because lagging- 
strand synthesis cannot fully replicate the telomere end 
(Fig. 1) [9,lZ]. Cells must possess mechanisms to solve 
this ‘end-replication problem’, to prevent telomeres from 
becoming progressively shorter during successive cell divi- 
sions, an outcome which would eventually reduce cell 
viability. An answer to this 1131 problem was supplied 
when Blackburn and colleagues discovered telomerasc, an 
enzyme that extends t&meres. 
Telomerases from lower eukaryotes have been characrer- 
ized and consist of two protein components and an RNA 
component {1+16]. The RNA component has an unusual 
role: it binds the incoming chromosome end and acts 
as a template for t-elomere extension (Fig. 2). These prop- 
erties make telomerase the only known polymerase that 
Figure 1 
The end-replication problem. During DNA replication, synthesis of the 
lagging strand requires an RNA primer (green). The primers that are 
extended by DNA polymerase are subsequently removed, leaving gaps. 
DNA polymerase cannot repair these gaps when they occur at the end of 
the klomere because of the absence of primer. As a result, one daughter 
strand will lack the DNA previously encoded by the terminal sequence. 
carries its own template with it. Protein components bind 
the RNA and participate in nucleotide polymerization. ‘Iivo 
protein components have been identified in Z&&yy;mena 
1151, neither of which has substantial identity with known 
polymerases. 
The protein components responsible for telomcrase activ- 
icy in mammalian cells have yet to be identified because, 
unlike Z&z,$~~ena and other ciliated protozoans that have 
thousands of chromosomes and high levels of telomerasc 
activity, each human cell possesses. very few molecules of 
tclomerase. What WC know about human telomerase is 
limited to the information from the sequence of its RNA 
component [ 171, mechanistic studies 1181, and the study of 
telomerase in lower organisms [ 161. 
The telomerase-cancer connection 
It is generally accepted that multiple genetic alterations 
must occur for cells to become malignant and that, once 
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immortal, cancerous cells undergo extensive proliferation 
during tumor growth and metastasis. As a result, they are 
more likely to require mechanisms to preserve functional 
telomeres. Studies showing the presence of telomerasc 
activity in tumor samples but not in adjacent normal tissue 
support this conclusion, suggesting that cancerous cells 
must reactivate or upregulate telomerase activity prior to 
estabhshmenc of an aggressive malignancy (Fig. 3) [5-S]. 
These studies have shown that telomerase activity is an 
excellent marker for malignancy, providing a valuable tool 
for tumors where diagnosis by other techniques is difficult. 
TeIomerase activity may also prove ro be a uscfu! prognos- 
tic indicator for the progression of a given cancer, enabling 
chemotherapy to be better taitored to the severity of the 
disease for an individual patient. Beyond USC as a marker, 
telomerase activity may be important, if not required, for 
sustained tumor growth, leading to the hypothesis that its 
inhibition may cause tumors to regress. 
Whether telomerasc is required fur cell immortality or 
tumor growth is in dispute, as some tumors and immortal 
cell lines do not contain detectable telomerase [19-211. In 
addition, yeast appears to be capable of utilizing telom- 
erase-independent pathways to maintain telomere length 
[ZZ]. Therefore ir is likely that telomerase activity will not 
always be necessary for cell immortality or tumor growth, 
even though greater than 85 % of all human malignancies 
studied to date do express the enzyme [S]. 
Studies of mice which have had their telomerase RNA 
genes disrupted are ongoing. This much-awairerd and cur- 
rently unpublished work will provide insights into telom- 
ere and telomerase biology, but the relevance of these 
studies ro human cancer must be evaluated with caution 
Figure 2 
Telomerase binds a telomeric end of a DNA 
chromosome and aligns it by recognition of 
the RNA template. The chromosome 3’ end 
is elongated with six nucfeotides 
complementary to the RNA to create the 
characteristic telomere repeat. A 
translocation event repositions the telomere 
to repeat the polymerization step. 
- 
because murinc telomere maintenance may not correlate 
well with that in humans. MUX m~~sc~~~s, the species used, 
possesses telomeres that are two to three times longer than 
those found in humans, and it may rake severa genera- 
tions for chromosome shortening or phenorypic changes to 
become apparenr. Moreover, normal mouse cells sponta- 
neously immortalize in culture whereas normal human 
cells do not [ZS], suggesting that mice and humans have 
evolved different strategies for telomere regulation. This 
suggestion is supported by findings that telomerase activ- 
ity is upregulated in murine tumors despite the presence 
of extremely long celomeres [24-261. 
Telomerase as a target for chemotherapy 
A dcfinicive understanding of rhe role of relomerase 
ii1 human cancer will require examination of each type 
of tumor, and the application of selective telomerase 
inhibitors would be of great vafue for this purpose. Telom- 
erase is an unusual target for chemotherapy because it is 
likely that celomerasc inhibitors will need to bc adminis- 
tered for weeks or months before an effect is observed. 
Telomerase therapeutics will need to be potent, have mild 
side effects, and be relatively inexpensive per dose. As 
te!omerase inhibitors will not- initially kill cells, ihey may 
not be useful as a primary rherapy. Their most likely appli- 
cation may be CO help keep tumors from recurring after 
chemotherapy or surgery, especially when used in combi- 
nation with other drugs. One possible source ofsiclr effects 
is the probable inhibition of telomerase in proliferating 
male germ cells and proliferative cells of renewal tissues, 
which also possess this activity. These cell types have, 
however, longer telomeres than do most tumor cells, and 
may be more likely to survive treatment with relomerase 
inhibitors (Fig. 3) 181. 
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Figure 3 -- 
potential effect of telometase inhibition [El. 
Stem and germ cells typically have longer 
teiomeres than cancer cells, so if telomerase 
is inhibited, shortening of telomeres may first 
lead to growth arrest in tumor cells. 
Strategies for the rational design of telomerase inhibitors 
The rational design of human telomerase inhibitors has 
been c%mplicated by the lack of pure enzyme, the failure 
to identify the amino-acid sequence of the protein compo- 
nents and the very limited sequence identity between the 
protein components of telomerase from lower organisms 
and known polymerascs. However, the RNA sequence pro- 
vides a characterized target, and studies of the enzyme 
have provided valuable mechanistic information. Inhibition 
of telomerase activity can be assayed either by monitoring 
the elongation of an oligonucleotide primer directly or by a 
PCR-based assay. The PCR-based assay is lOOO-fold more 
sensitive than the direct assay [Z], but care must be taken 
that added inhibitoc_s do not block any step in the amplifi- 
cation process. Potential molecular targets for telomerase 
inhibitors include the following (Fig. 4). 
The RNA’ template 
This is an attractive target for inhibitors because the 
sequence of the human telomerase RNA is known 1171. 
The dependence on an RNA template suggests that com- 
plementary oligonucleotides should be inhibitors, and DNA 
oligonucleotides have been shown to inhibit ciliate {14] and 
mammalian [17,2?] telomerases. Inhibition of other cellular 
processes by antisense oligonudeotides directed against 
mRNA have met with limited success. However, unlike 
mRNA targets, the celomcrase RNA is intrinsically accessi- 
ble because of its need to bind the exposed telomere end, 
making it an ideal target for recognition by oligonucleotides. 
Inhibition of telomerase activity by DNA oligonucleotides 
requires relatively high concentrations of oligomer and 
relatively long sequences [14,17,273. Shorter (I 1-13 
nucleotides) peptide nucleic acids (PNAs) bind to 
complementary sequences with much higher melting tem- 
peratures than analogous DNA oligomers because of their 
lack of charge, and PNAs inhibit telomerase activity in 
O&V when present in concentrations as low as 1 nM [2X]. 
Methods for the delivery of PNAs across cell membranes 
have not been demonstrated, but if this can be done, 
PNAs or similar oligomers should be excellent tools for 
studying the cellular role of telomerase and may be useful 
lead compounds for therapy. 
The primer anchor site 
Like other polymerases, telomerase activity depends on 
interactions between one or more of its protein compo- 
nents-and DNA [lh]. These interactions stabilize the 
complex prior to initiation of polymerization, and help 
transiocate the newly extended telomere so that another 
round of synthesis can begin. Evidence for the strength 
of these non-Watson-Crick DNA-telomerase interactions 
is provided by the finding that telomerase uses an artifJ- 
cial primer with an apparent K, of 10 nM [28], even 
though the primer has only a four-base complementarity 
with the RNA template. Although guidelines for design 
of specific inhibitors at the anchor site are more obscure 
than those for .inhibition at the RNA template, the impor- 
cance of the site suggests that the design of selective 
inhibitors should be possible. Indeed, phosphororhiorate 
oiigonucleotides with no complementarity to the RNA 
template effccGvely inhibit telomerase activity in the 
nanomolar range [2,8], presumably by exploiting electro- 
static interactions normally used to stabilize protein 
binding to the phosphodiester backbone of DNA primers. 
Small, structured polyanionic compounds may be simi- 
larly effective inhibitors, although their intracellular 
delivery may present problems. 
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Figure 4 
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Potential targets for telomerase inhibition. Targets include the RNA 
template, which binds the telamere by Watson-Crick base pairing, 
the anchor site, which binds the lelomere by non-sequence-specific 
recognition, the protein active site responsible for nucleotide 
polymerization, and non-template RNA. 
The polymsrase active site 
Like DNA polymerase or reverse transcriptase, telom- 
erase uses DNA nucleotides to extend a primer. Therc- 
fore, in spite of the lack of substantial homology between 
telornerase and other proteins, nucleotide-based inhibitors 
wili bhck its action as they do with other polymerases. 
Moreover, the dissimilarity between telomerase and other 
polymerases may be advantageous, since structural differ- 
ences may allow the design of inhibitors that are selective 
for telomerase. Blackburn and Strahl [29] have already 
shown that nucleotide analogs inhibit tetomerase activity 
ill Z&O, although evidence for a9a &JO effects is unclear 
and may even suggest the presence of a mechanism for 
tdomcrase-independent telomere maintenance in mam- 
malian cell lines [30]. Screening for more potent and more 
specific inhibitors is necessary to define the potential for 
active-site directed molecules. 
The RNA-protein interface 
As a ribonucleoprotein, telomerase requires proper assem- 
bly of its essential RNA and protein components, and 
disruption of this assembly would inhibit activity. This 
approach has already been attempted, and cells expressing 
an antisense transcript complementary to the telomerase 
RNA in HeLa cells underwent cell crisis [17]. Similarly, 
small molecules that obstruct proper assembly, perhaps 
analogs of regions of the RNA, might also block this 
association and prevent the synthesis of active telomerase. 
Alternatively, molecules chat bind the RNA component 
may disrort chc template and prevent its proper function- 
ing. The secondary structure of TetP-a~~me~la telomerase 
RNA has been predicted [31], and this prediction suggests 
the identity of a domain that may be involved in protein 
binding [32]. Although such predictions await structural 
confirmation, they afford a useful starting point for 
inhibitor design. 
Outlook for telomerase inhibition 
The uniqueness of telomerase as ?,n enzyme and as a 
target for chemotherapy make it i&possible to predict 
whether its inhibition will lead to improved outcomes for 
cancer patients. What is certain is that the discovery of 
inhibitors is critical for understanding the basic cell biology 
and biochemistry of telomerase. This knowledge will facil- 
itate the synthesis of optimized inhibitors combining high 
potency and selectivity with good pharmacokinetic proper- 
ties. OnIy with thesq molecules in hand wiI1 it be possible 
to test definitively the link between &omerase and 
cancer. Finally, it should be noted that telomerase may be 
a target for parasitic and fungal d+seases as well, leading to 
even wider application of selective telomerase inhibitors. 
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